Brivaracetam
- Generic Name
- Brivaracetam
- Brand Names
- Briviact, Briviact (in Italy: Nubriveo)
- Drug Type
- Small Molecule
- Chemical Formula
- C11H20N2O2
- CAS Number
- 357336-20-0
- Unique Ingredient Identifier
- U863JGG2IA
Overview
Brivaracetam is a racetam derivative of levetiracetam used in the treatment of partial-onset seizures. Brivaracetam binds SV2A with 20 times higher affinity than levetiracetam . It is available under the brand name Briviact made by UCB. Briviact received FDA approval on February 19, 2016 .
Background
Brivaracetam is a racetam derivative of levetiracetam used in the treatment of partial-onset seizures. Brivaracetam binds SV2A with 20 times higher affinity than levetiracetam . It is available under the brand name Briviact made by UCB. Briviact received FDA approval on February 19, 2016 .
Indication
Used as adjunctive therapy for partial-onset seizures in patients 16 years of age or older.
Associated Conditions
- Partial-Onset Seizures
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2024/03/18 | Phase 3 | Recruiting | |||
2024/03/15 | Phase 1 | Completed | |||
2023/06/12 | Phase 1 | Not yet recruiting | |||
2022/12/07 | Phase 3 | Completed | |||
2022/11/18 | Phase 1 | Active, not recruiting | |||
2022/04/07 | Phase 1 | Completed | |||
2021/11/05 | Phase 3 | Completed | |||
2021/09/01 | Early Phase 1 | Active, not recruiting | |||
2021/05/12 | Phase 1 | Completed | |||
2021/01/20 | Phase 3 | Recruiting |
FDA Approved Products
Product Name | Manufacturer | Route | Strength | Approved | NDC Code |
|---|---|---|---|---|---|
ORAL | 75 mg in 1 1 | 2023/05/24 | 50474-670 | ||
ORAL | 25 mg in 1 1 | 2023/05/24 | 50474-470 | ||
ORAL | 100 mg in 1 1 | 2023/05/24 | 50474-770 | ||
ORAL | 10 mg in 1 1 | 2023/05/24 | 50474-370 | ||
INTRAVENOUS | 50 mg in 5 mL | 2023/05/24 | 50474-970 | ||
ORAL | 10 mg in 1 mL | 2023/05/24 | 50474-870 | ||
ORAL | 50 mg in 1 1 | 2023/05/24 | 50474-570 |
EMA Approved Products
Medicine Name | EMA Number | Auth. Holder | Country | Drug Type | Status | Issued | Opinion | Revision |
|---|---|---|---|---|---|---|---|---|
EMEA/H/C/003898 | Belgium | N/A | Authorised | 2016/01/13 | N/A | 25 |
HSA Approved Products
Product Name | Manufacturer | Dosage Form | Strength | Approved | Approval No. |
|---|
No HSA products found
No HSA products found for this drug
NMPA Approved Products
Product Name | Approval No. | Manufacturer | Dosage Form | Trade Name | Strength | Type | Status | Date | Import |
|---|---|---|---|---|---|---|---|---|---|
国药准字H20244272 | 片剂 | N/A | 50mg | Chemical Drug | Approved | 2024/06/28 | Domestic | ||
国药准字H20244271 | 片剂 | N/A | 25mg | Chemical Drug | Approved | 2024/06/28 | Domestic |
PPB Approved Products
Product Name | Registration Code | Company | Category | Sale Type | Reg. Date |
|---|
No PPB products found
No PPB products found for this drug
TGA Approved Products
Product Name | ARTG ID | Sponsor | Status | Reg. Date | Ingredient |
|---|---|---|---|---|---|
243795 | Active | 2016/08/04 | brivaracetam | ||
243796 | Active | 2016/08/04 | brivaracetam | ||
243792 | Active | 2016/08/04 | brivaracetam | ||
243797 | Active | 2016/08/04 | brivaracetam | ||
243798 | Active | 2016/08/04 | brivaracetam | ||
243793 | Active | 2016/08/04 | brivaracetam |
© Copyright 2025. All Rights Reserved by MedPath